

## AYUDAS INVESTIGADOR AECC 2022

### Adjudicatarios

**Dr. Alejandro Prados Martín**

Institut de Recerca Biomèdica - IRB  
Barcelona

Unveiling Fibroblast Dynamics to treat  
Advanced Colorectal Cancer

**Dr. Víctor Manuel García Martínez**

Instituto de investigación Hospital 12  
de octubre - i+12

New perspectives to improve bacillus  
Calmette-Guerin (BCG)-  
immunotherapy in non-muscle  
invasive bladder cancer

**Dra. Jeannine Diesch**

Institut de Recerca Contra la  
Leucèmia Josep Carreras-IJC

A functional approach to accelerate  
the development of combinatorial  
drug therapies in blood cancers

**Dr. Kass Youssef Khalil**

Instituto de Neurociencias de  
Alicante, UMH-CSIC

The role of cancer cells-neurons  
interactome in breast cancer  
evolution to malignancy and  
resilience to therapy

**Dra. Talia Velasco Hernandez**

Institut de Recerca Contra la  
Leucèmia Josep Carreras-IJC

Identificación of new therapeutic  
targets to avoid relapse  
and chemoresistance in Acute

**Dra. Diana Aguilar Morante**

Instituto de Biomèdica de Sevilla  
(IBIS)

Unravelling functional interplay  
between R-loops and Replication-  
Transcription Conflicts as a novel  
therapeutic target in High-Risk  
neuroblastoma tumours

**Dra. Alba Rodríguez García**

Fundació Clínic per a la Recerca  
Biomèdica

Next-generation of chimeric antigen  
receptor (CAR)-T cells for the  
treatment of solid tumors

**Dr. Jonathan Barroso Gonzalez**  
Centro Nacional Investigaciones  
Oncológicas (CNIO)

Development of specific TDP2  
inhibitors to enhance cancer cell  
sensitivity to TOP2 poisons. A  
synthetic lethal combination for ATM-  
deficient tumors?

**Dra. María Arechederra**  
Cima Universidad de Navarra

Innovative liver cancer diagnostic and  
therapeutic enquiring (LIVCAN-DATE)

**Dra. Amaia Zabala Letona**  
CIC bioGUNE

Metabolic control of splicing in cancer  
cells (METABOSPLICE)

**Dr. Jonathan Barroso**  
Centro Nacional Investigaciones  
Oncológicas (CNIO)

Development of specific TDP2  
inhibitors to enhance cancer cell  
sensitivity to TOP2 poisons. A  
synthetic lethal combination for ATM-  
deficient tumors?